I have read the paper. Now let me verify a few harsh critic claims against the actual numbers, then do calibration retrievals.Round 1 bracket: Based on topical anchors, the paper looks like it sits in the 4–6 range. The paper has a clear, empirically grounded story but suffers from structural concerns (potential leakage, overclaiming "consistent degradation"). Let me narrow.Round 2 narrowing complete. Most relevant anchors:
- **LLaPA** (4.75, Reject): retrieval-augmented protein LLM for EC prediction. Reviewer 3 raises *exactly* the same leakage concern as our harsh critic. Strong match — our paper is in similar territory but is more of a position paper than a model paper.
- **SEPIT** (6.25, Reject): structure-enhanced protein instruction tuning. Stronger methodological contribution than this paper.
- **CURIE** (6.40, Accept): scientific benchmark for LLMs. Different scope.
- **Does your model understand genes?** (4.75, Reject): cross-modality benchmark for biological models. Comparable scope.

This paper falls closest to LLaPA-tier (4.5–5.0): well-executed empirical paper but with a structural leakage concern in evaluation and overclaimed headline. Now writing the review.

## Summary
This paper argues that current Scientific LLMs are "lost in tokenization" — neither the sequence-as-language nor the sequence-as-modality paradigm gives reliable biomolecular understanding. As an alternative, the authors run standard bioinformatics tools (InterProScan/Pfam, BLASTp against Swiss-Prot, ProTrek as a fallback) over a query protein and feed the resulting structured text annotations to an off-the-shelf LLM. On protein QA tasks (function, pathway, subcellular localization), this "context-driven" pipeline outperforms specialized Sci-LLMs (Intern-S1, Evolla, NatureLM) on benchmark, time-stratified, and small-scale novel-sequence (Rhodopsin, PETase) settings, and is much cheaper at batch scale.

## Strengths
- **Strong empirical contrast between paradigms.** Across seven models on three tasks, context-only consistently dominates sequence-only by very large margins (e.g., Intern-S1: 43.33 → 86.15; DeepSeek-v3: 40.77 → 84.99 in Table 1). This is real, useful documentation of the current state of Sci-LLMs.
- **Layer-wise representational analysis of Evolla (Section 5.3, Figure 3).** Tracing SaProt → Q-Former → decoder ARI (0.945 → 0.916 → 0.809) gives concrete, mechanistic evidence of semantic-alignment degradation specifically inside a sequence-as-modality model. This is the cleanest evidence in the paper.
- **Efficiency analysis (Section 5.5, Table 2).** ~154× speedup and ~30× cost reduction over Evolla in batch mode is a substantive practical result, not a marginal optimization.
- **Wet-lab evaluation on novel sequences (Section 5.6).** Using unpublished Rhodopsin and PETase variants absent from Swiss-Prot is a meaningful attempt at out-of-distribution testing; even if not fully airtight (see below), it goes beyond purely in-database benchmarking.

## Weaknesses

### Fatal
None — the structural concerns below are serious but the paper still documents a real empirical regularity.

### Major

- **Evaluation leakage between the toolchain and the ground truth.** The benchmark labels are excerpted directly from Swiss-Prot entries (Section 5.1), and the "context" delivered by the pipeline consists of (i) Pfam/InterProScan domain annotations and (ii) GO terms transferred from BLASTp homologs in Swiss-Prot — i.e., the same database family that supplies the labels. The paper's defense in Section 4 ("intrinsic analysis rather than identity lookup", "homology-based inference rather than direct annotation matching") justifies the method as a *bioinformatics tool*, but does not address the *evaluation* concern: for queries with strong Swiss-Prot homologs, the context essentially carries the answer. This makes Context-Only vs. Sequence-Only a comparison between annotation transfer and zero-shot prediction, rather than between paradigms. A leakage-controlled setting (e.g., excluding homologs above some sequence-identity threshold) is needed to support the headline.

- **The "consistently degrades" claim is overstated for general LLMs.** Table 1 shows that Sequence+Context vs. Context-Only goes in opposite directions across models: degradation is real for the specialized Sci-LLMs (Intern-S1 84.03 vs. 86.15; Evolla 70.53 vs. 74.02), but for the general LLMs the direction often reverses or is essentially tied (DeepSeek-v3 86.03 vs. 84.99; GPT-5 76.45 vs. 75.76; Qwen3-235B 85.90 vs. 84.99; Gemini-2.5-Pro 86.98 vs. 87.19). The abstract phrase "consistently and substantially outperforms all other modes" and the Section 5.1 claim of "consistent performance degradation" do not match the numbers as reported. The honest statement is that adding sequence hurts the specialized Sci-LLMs while having little effect on general LLMs.

- **The "tokenization dilemma" diagnosis is asserted rather than isolated.** The empirical contrast does not, on its own, distinguish "tokenization destroys functional motifs" from a much simpler explanation: LLMs are bad at de novo functional inference from raw sequence and good at reading annotation text. Section 5.2 attempts to substantiate "weak representation" by comparing LLM output embeddings of Sci-LLMs against Qwen-text-embeddings of the structured context — these are not the same kind of object. The ARI=0.958 for "Ours" largely reflects that text embeddings cluster functional annotation strings whose category is already in the text. The only place this diagnosis gets clean support is the within-Evolla layer-wise analysis in Section 5.3.

### Minor

- **No statistical reporting on the central evidence.** Differences in Sequence+Context vs. Context-Only are often within 0.2–3.5 points without confidence intervals, variance over judge prompts, or seeds. Given that several of these are the basis for the rhetorical thrust, at minimum a bootstrap CI over the test set is needed.

- **The temporal degradation curve (Section 5.4, Figure 4) is partly a homology-availability curve.** The paper itself attributes the "Ours" slope of −0.618 to "diminishing availability of rich, homologous information in the knowledge bases", which is exactly the standard recency curve of any annotation-transfer method. This documents the operating envelope of the approach more than it argues for the new paradigm; the framing in the takeaway should be tempered.

- **Wet-lab generalization is partly explained by trivial Pfam detection.** Rhodopsin (opsin/7TM) and PETase (α/β hydrolase, PETase-specific motifs) are families with very strong Pfam signatures that InterProScan should detect on novel members. Reporting 100% / 97.3% is consistent with "Pfam still finds these families" rather than with the much stronger generalization claim implied in Section 5.6. An evaluation on sequences whose ground-truth fields are not derivable from Pfam+homology would carry more weight.

- **Novelty framing vs. agent-based prior work.** Section 2.3 mentions GeneAgent and ChemCrow but only in passing; the proposed pipeline is methodologically close to tool-augmented LLM agents pre-formatted into a static prompt. The "paradigm-resolving" framing is stronger than what differentiates this work from that line.

### Trivial
- "Peruz et al., 2022" in Section 1 appears to be a citation key issue.

## Nice-to-Haves
- A regime-stratified table reporting performance separately on (i) queries with strong Swiss-Prot homologs, (ii) queries with only weak homologs, and (iii) genuine orphans, so readers can see the operating envelope of the proposed paradigm.
- A direct comparison against an LLM-as-agent baseline that calls these same tools at inference time (rather than receiving pre-formatted output), since that is the most natural competing paradigm.
- For the mechanistic claim: an ablation that decouples "tokenization noise" from "answer is in the prompt," e.g., a context variant that retains structural/biophysical features but strips overt functional terminology.
- Section 5.2 should compare commensurable objects (e.g., output embeddings under the same embedder, or hidden states on the same input format).

## Removed Points
*These points are flagged to be removed, treat them with caution.*

- *(From harsh critic)* "A second architecture beyond Evolla (e.g., BioReason) is needed to support the paradigm-level claim." — The paper does evaluate seven distinct LLMs across two specialized Sci-LLM paradigms and four general LLMs; the paradigm-level claim is broader than a single architecture choice. Demoted to nice-to-have.
- *(From strength finder)* "Table 1 shows that for every model tested, Sequence+Context underperforms Context-Only." — **Factually inverted.** For 4/7 models in Table 1 (DeepSeek-v3, Gemini-2.5-Pro, GPT-5, Qwen3-235B) the relationship reverses or is tied. This claim conflicts with a verified weakness; the weakness wins.
- *(From strength finder)* "Wet-lab validation confirms out-of-distribution generalization." — Kept the basic strength but **weakened**: Rhodopsin and PETase have strong Pfam signatures, so the test is not as adversarial as framed.
- *(From harsh critic)* Concerns phrased as "for a tool to be reliable we'd need…" without a specific anchor in the paper. Removed as area-of-concern sweep.

## Novel Insights
None beyond the paper's own contributions. The empirical observation that tool-pipeline + general LLM dominates end-to-end Sci-LLMs on annotation-style QA is what this paper actually establishes; the broader "tokenization dilemma resolved" framing exceeds what the evidence supports.

## Suggestions
- Re-run the central comparison with a sequence-identity cutoff (e.g., 30%) on BLAST hits, so that the test answers cannot be transferred near-deterministically from a homolog. Report the gap between Context-Only and Sequence-Only in that regime.
- Stratify Table 1 results by homology-availability bins (strong/weak/none) so readers can see when the proposed approach actually outperforms.
- Rephrase the headline claim to match Table 1: adding sequence hurts specialized Sci-LLMs but is approximately neutral for general LLMs. The current "consistently degrades" wording is not supported.
- Move Section 5.2 either to a within-model comparison or to a within-embedder comparison; the cross-embedder comparison cannot anchor a representational-quality conclusion.
- Position the work explicitly relative to tool-augmented LLM agents (GeneAgent, ChemCrow), since the proposed pipeline is closer to that line than the introduction implies.

## Evaluation Axes
- **Originality:** Moderate. The empirical comparison is well-organized but the proposed pipeline is close to the established tool-augmented LLM line; the novelty is in framing and breadth.
- **Importance:** The question of how to integrate biomolecular sequences into LLMs is real and timely.
- **Support for claims:** The narrower claim (context > sequence on annotation QA) is well-supported; the stronger claims ("consistent degradation", "tokenization dilemma resolved") are not.
- **Soundness of experiments:** Reasonable in scope; weakened by structural leakage between the toolchain and the labels, by missing variance/significance, and by the incommensurable comparison in Section 5.2.
- **Clarity:** Generally clear; the formalism in Section 3 is helpful.
- **Value to the community:** Useful empirical documentation that today's tool-augmented pipelines outperform specialized end-to-end Sci-LLMs on annotation tasks; readers should understand the leakage caveat to apply the takeaway correctly.

## Score and Decision

**Anchor comparison (all rounds):**

| Path | Avg score | Round | Comparison to paper |
|---|---|---|---|
| ProteinAdapter (jqx5XI4Yr3) | 3.40 | R1 | Weaker — paper is more thorough than this clear-reject anchor. |
| Comparing pLMs (IEZjjDX0iC) | 3.00 | R1 | Weaker — paper has more substantive findings. |
| G2T-LLM (hrMNbdxcqL) | 3.00 | R1 | Weaker. |
| Broadening Discovery (N4lUNwEn1c) | 3.00 | R1 | Weaker. |
| MeToken (noUF58SMra) | 5.80 | R1 | Stronger methodological contribution; accepted. Paper under review is weaker. |
| Hierarchical Graph Tokenization (4VmagzA2Tp) | 4.50 | R1 | Comparable tier; similar mixed empirical-position character. |
| bio2token (6ktqrC1Bpf) | 5.00 | R1 | Stronger methodological depth; rejected at 5.0. |
| SEPIT (8CKgS18uWx) | 6.25 | R1, read | Has a real architectural contribution + new dataset; paper under review is weaker. |
| ProtComposer (0ctvBgKFgc) | 8.00 | R1 | Far stronger. |
| Discrete Walk-Jump (zMPHKOmQNb) | 8.00 | R1 | Far stronger. |
| DEPT (vf5aUZT0Fz) | 8.00 | R1 | Far stronger. |
| LLM-SR (m2nmp8P5in) | 8.00 | R1 | Far stronger. |
| Does your model understand genes? (GDDqq0w6rs) | 4.75 | R2, read | Comparable scope (cross-modality bio benchmark); paper under review is in the same tier. |
| LLaPA (AK9uRqzLjt) | 4.75 | R2, read | **Strongest match** — also a retrieval-augmented protein LLM; reviewer 3 raises the same leakage concern. Paper under review is comparable. |
| Genomics Long-Range Benchmark (8O9HLDrmtq) | 5.00 | R2 | Comparable tier. |
| Long-context Protein LM (Et0SIGDpP5) | 4.25 | R2 | Slightly weaker. |
| Unearthing Domain Knowledge (8EM1A6qfX5) | 5.00 | R2 | Different topic, similar tier. |
| KG-LLM Trustworthy (DOA1WSPZSi) | 4.75 | R2 | Different topic, similar tier. |
| CURIE (jw2fC6REUB) | 6.40 | R2 | Stronger benchmark scope; accepted. |
| SciKnowEval (pXUAiJshdh) | 5.50 | R2 | Stronger benchmark breadth. |
| VisScience (wgKW4U7ktq) | 4.75 | R2 | Different scope. |
| Closing the Gap (4ndvumlZak) | 4.50 | R2 | Different topic, similar tier. |
| Contextualizing biological perturbation (5WEpbilssv) | 4.60 | R2 | Comparable bio-LLM thesis; accepted at 4.60. |
| LLM Spark (0sJ8TqOLGS) | 5.25 | R2 | Different topic, similar tier. |

**Round 1 bracket:** [3.5, 6.5]. **Round 2 narrowing:** The paper sits closest to LLaPA (4.75) — same domain, same retrieval-style augmentation, same leakage concern flagged by an attentive reviewer. It is slightly stronger than LLaPA in scope (seven models, time-stratified, wet-lab) but weaker in that the central headline ("consistent degradation", "tokenization dilemma resolved") is overstated, and it lacks a methodological novelty beyond the pipeline. It is weaker than SEPIT (6.25, rejected) and MeToken (5.80, accepted), both of which contribute genuine architectural ideas. It is roughly in the same tier as "Does your model understand genes?" (4.75) — a careful but somewhat under-claimed empirical comparison paper.

Final placement: just below the LLaPA / "gene understanding" tier — the leakage concern is more central to the headline here than in LLaPA, and the "consistently degrades" wording is plainly inconsistent with the table.

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>